Researchers have made a significant breakthrough in treating acquired hypothalamic obesity (HO), a rare condition that leads to excessive weight gain due to hypothalamic injury. The European Commission has approved IMCIVREE® (setmelanotide) for use in adults and children aged four and older with this condition. This approval marks the first time a therapy specifically targeting acquired HO has been authorized, providing hope for the estimated 10,000 people affected in Europe.

For those struggling with weight management due to hypothalamic dysfunction, this new treatment could be life-changing. In clinical trials, participants using setmelanotide experienced an average reduction in body mass index (BMI) of 16.5% after one year, compared to a 3.3% increase in those receiving a placebo. This means that people with acquired HO could potentially see significant improvements in their weight and hunger control, which are crucial for overall health and well-being.

The evidence supporting this treatment comes from a robust Phase 3 clinical trial involving 120 participants, which demonstrated a statistically significant reduction in BMI. While the results are promising, it’s important to note that this treatment is still relatively new and has only been approved in Europe and the U.S. for specific conditions related to hypothalamic obesity. The most common side effects reported include nausea, vomiting, and skin reactions, but the treatment was generally well tolerated.

If you or someone you know is affected by acquired hypothalamic obesity, it’s worth discussing this new treatment option with a healthcare provider. They can provide insights into whether IMCIVREE® could be appropriate based on individual health needs and circumstances.

Source: globenewswire.com